These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 21570509)

  • 1. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
    Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
    J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
    Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
    J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
    Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
    Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
    Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
    Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban in patients with a recent acute coronary syndrome.
    Mega JL; Braunwald E; Wiviott SD; Bassand JP; Bhatt DL; Bode C; Burton P; Cohen M; Cook-Bruns N; Fox KA; Goto S; Murphy SA; Plotnikov AN; Schneider D; Sun X; Verheugt FW; Gibson CM;
    N Engl J Med; 2012 Jan; 366(1):9-19. PubMed ID: 22077192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
    Cavender MA; Gibson CM; Braunwald E; Wiviott SD; Murphy SA; Toda Kato E; Plotnikov AN; Amuchástegui M; Oude Ophuis T; van Hessen M; Mega JL
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):468-74. PubMed ID: 25318481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
    Korjian S; Braunwald E; Daaboul Y; Mi M; Bhatt DL; Verheugt FWA; Cohen M; Bode C; Burton P; Plotnikov AN; Gibson CM
    Am J Cardiol; 2018 Dec; 122(11):1896-1901. PubMed ID: 30340765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.
    Gibson CM; Levitan B; Gibson WJ; Yee MK; Murphy SA; Yuan Z; Chakrabarti AK; Lee M; Braunwald E
    J Am Coll Cardiol; 2018 Jul; 72(2):129-136. PubMed ID: 29976285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban: a review of its use in acute coronary syndromes.
    Plosker GL
    Drugs; 2014 Mar; 74(4):451-64. PubMed ID: 24535922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.